Cryosurgery of Prostate — NCD 123 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 123 governing cryosurgery of the prostate, effective March 7, 2026. Here's what billing teams need to act on now.

CMS cryosurgery of the prostate coverage policy under NCD 123 Medicare draws a hard line between two clinical scenarios: primary treatment for localized prostate cancer and salvage therapy after radiation failure. The policy does not list specific CPT or HCPCS codes, so your team needs to work from clinical documentation and ICD-10 staging to support medical necessity. Get that documentation workflow locked down before the effective date of March 7, 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Cryosurgery of Prostate — NCD 123
Policy Code	NCD 123 Medicare
Change Type	Modified
Effective Date	2026-03-07
Impact Level	High
Specialties Affected	Urology, Radiation Oncology, Oncology, Inpatient and Outpatient Hospital Billing
Key Action	Audit documentation for primary vs. salvage therapy distinctions before submitting any cryosurgical ablation of the prostate claim

---

CMS Cryosurgery of the Prostate Coverage Criteria and Medical Necessity Requirements 2026

NCD 123 is the National Coverage Determination governing Medicare coverage of cryosurgical ablation of the prostate (CSAP). CMS treats this procedure as safe, effective, and medically necessary — but only when the patient meets specific clinical criteria. Billing without those criteria documented is a fast path to claim denial.

Primary Treatment Coverage

CMS covers cryosurgery of the prostate as primary treatment for patients with clinically localized prostate cancer at Stages T1 through T3. That's the straightforward scenario. Your documentation needs to confirm localized disease and the staging — T1, T2, or T3 — before the claim goes out.

There's no ambiguity in the primary treatment rule. If the staging is documented and the disease is localized, the procedure meets medical necessity under this coverage policy. The clinical note needs to reflect that directly, not leave a reviewer guessing.

Salvage Therapy Coverage After Radiation Failure

This is where NCD 123 gets precise — and where most claim denials will happen. Cryosurgery of the prostate as salvage therapy is only covered when the patient meets all of the following:

All three conditions in criterion two are written as "or," not "and." One is enough. But criterion one — documented radiation failure — is non-negotiable. No radiation trial, no salvage coverage. Full stop.

Your clinical documentation must show the radiation therapy course, the evidence of failure, and the current staging and lab values. A claim for salvage CSAP without that sequence documented will not survive review.

Prior Authorization and Reimbursement Considerations

NCD 123 does not explicitly require prior authorization. That said, cryosurgical ablation of the prostate is a high-dollar procedure billed across inpatient and outpatient hospital settings, as well as under physician services. Each setting carries its own reimbursement structure and documentation requirements. Check with your Medicare Administrative Contractor for any local coverage determination that may layer additional requirements on top of this NCD before you submit.

---

CMS Cryosurgery of the Prostate Exclusions and Non-Covered Indications

The exclusions in NCD 123 are narrow but absolute. Miss them and you're looking at a denial with no path to appeal.

Salvage Therapy Before June 30, 2001

Cryosurgery of the prostate as salvage therapy is not covered for any services performed before June 30, 2001. This is a historical exclusion that rarely applies to current claims, but it matters if your team handles any late-filed or retroactive billing situations.

Salvage After Non-Radiation Primary Treatment

This is the most operationally significant exclusion. CMS does not cover cryosurgery as salvage therapy when the failed primary treatment was anything other than radiation. If a patient's first-line treatment was surgery, hormone therapy, or any other non-radiation approach, cryosurgery as a follow-on procedure is not covered under this policy.

The policy states this directly: salvage CSAP is only covered after the failure of radiation therapy. No other failed primary treatment qualifies. If your urology or oncology team is referring patients for salvage CSAP after non-radiation primary therapy, that needs to be flagged before the claim is built — not after it's denied.

---

Coverage Indications at a Glance

---

CMS Cryosurgery of the Prostate Billing Guidelines and Action Items 2026

The modified NCD 123 took effect March 7, 2026. If your team is still running documentation and charge capture processes built around older assumptions, here's what to do now.

Copy Action Items

If your mix includes a high volume of salvage CSAP cases or complex oncology billing, loop in your compliance officer before submitting claims under the modified policy. The salvage criteria are specific enough that one misread can generate a pattern of denials that triggers a larger review.

---

CPT, HCPCS, and ICD-10 Codes for Cryosurgery of the Prostate Under NCD 123

Covered CPT Codes (When Selection Criteria Are Met)

NCD 123 does not list specific CPT or HCPCS codes. The policy defines coverage by clinical indication and medical necessity criteria, not by procedure code. Work with your coding team and MAC to confirm which codes apply to cryosurgical ablation of the prostate billing in your jurisdiction.

Not Covered / Experimental Codes

No specific codes are designated as non-covered or experimental in NCD 123. Coverage exclusions are tied to clinical scenarios — salvage after non-radiation therapy and services before June 30, 2001 — not to specific procedure codes.

Key ICD-10-CM Diagnosis Codes

NCD 123 does not enumerate specific ICD-10-CM codes. However, the policy's coverage criteria map directly to prostate cancer staging codes. Your coding team should confirm the appropriate malignant neoplasm of prostate codes that reflect T1–T3 staging for primary treatment claims, and recurrent disease codes for salvage therapy claims. Your MAC's local coverage determination will likely specify which ICD-10 codes support medical necessity for each scenario.

---